Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP978427.RAeIPMW1C2Yl3BNVd7ycsGp2yUYYUt5IyhQpIiIdZ_vHc130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP978427.RAeIPMW1C2Yl3BNVd7ycsGp2yUYYUt5IyhQpIiIdZ_vHc130_assertion type Assertion NP978427.RAeIPMW1C2Yl3BNVd7ycsGp2yUYYUt5IyhQpIiIdZ_vHc130_head.
- NP978427.RAeIPMW1C2Yl3BNVd7ycsGp2yUYYUt5IyhQpIiIdZ_vHc130_assertion description "[The development of novel technologies, such as massively parallel DNA sequencing, has led to the identification of several novel recurrent gene mutations, such as DNA methyltransferase (Dnmt)3a, ten-eleven-translocation oncogene family member 2 (TET2), isocitrate dehydrogenase (IDH)1/2, additional sex comb-like 1 (ASXL1), enhancer of zeste homolog 2 (EZH2) and ubiquitously transcribed tetratricopeptide repeat X chromosome (UTX) mutations in acute myeloid leukemia (AML) and other myeloid malignancies.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP978427.RAeIPMW1C2Yl3BNVd7ycsGp2yUYYUt5IyhQpIiIdZ_vHc130_provenance.
- NP978427.RAeIPMW1C2Yl3BNVd7ycsGp2yUYYUt5IyhQpIiIdZ_vHc130_assertion evidence source_evidence_literature NP978427.RAeIPMW1C2Yl3BNVd7ycsGp2yUYYUt5IyhQpIiIdZ_vHc130_provenance.
- NP978427.RAeIPMW1C2Yl3BNVd7ycsGp2yUYYUt5IyhQpIiIdZ_vHc130_assertion SIO_000772 23760684 NP978427.RAeIPMW1C2Yl3BNVd7ycsGp2yUYYUt5IyhQpIiIdZ_vHc130_provenance.
- NP978427.RAeIPMW1C2Yl3BNVd7ycsGp2yUYYUt5IyhQpIiIdZ_vHc130_assertion wasDerivedFrom befree-20150227 NP978427.RAeIPMW1C2Yl3BNVd7ycsGp2yUYYUt5IyhQpIiIdZ_vHc130_provenance.
- NP978427.RAeIPMW1C2Yl3BNVd7ycsGp2yUYYUt5IyhQpIiIdZ_vHc130_assertion wasGeneratedBy ECO_0000203 NP978427.RAeIPMW1C2Yl3BNVd7ycsGp2yUYYUt5IyhQpIiIdZ_vHc130_provenance.